GlassScriptPhysician profile
Kelly Macdonald
NPI 1487726469
$6,225.19
in general payments reported to CMS, 2019-2025
27 companies · $1,247 in 2025
The $1,247 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $952 · 2020: $482 · 2021: $585 · 2022: $1,189 · 2023: $824 · 2024: $946 · 2025: $1,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,016.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,677.82 | 2019-2025 | Myday Contact Lens |
| Alcon Vision LLC | $953.57 | 2019-2025 | Precision 1, Total30, Precision7 |
| Bausch & Lomb Americas INC. | $592.61 | 2022-2025 | Infuse, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $431.55 | 2019-2021 | |
| Allergan, INC. | $352.64 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $349.00 | 2019-2025 | Cequa |
| Lkc Technologies, INC. | $284.95 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $276.19 | 2019-2023 | |
| Oyster Point Pharma, INC. | $217.02 | 2022-2024 | Tyrvaya |
| Dompe US, INC. | $203.30 | 2021-2025 | Oxervate |
| Abbvie INC. | $106.61 | 2022-2024 | |
| Horizon Therapeutics Plc | $102.84 | 2022-2023 | Tepezza |
| Topcon Healthcare, INC. | $91.52 | 2025 | |
| Biotissue Holdings INC. | $83.24 | 2023-2025 | |
| Samsara Vision | $81.62 | 2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $73.75 | 2022-2025 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $72.14 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $61.47 | 2021-2022 | |
| Maculogix, INC. | $61.08 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $30.70 | 2025 | Xdemvy |
| Johnson & Johnson Vision Care, INC. | $27.54 | 2019-2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Visioneering Technologies, INC. | $18.72 | 2019 | |
| Lombart Brothers, INC. | $15.06 | 2024 | Opd-III |
| Harrow Eye, LLC | $14.23 | 2024 | Vevye |
| Quidel Corporation | $13.90 | 2021 | |
| Shire North American Group INC | $12.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kelly Macdonald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.